Neuphoria Therapeutics Inc (NEUP) Return on Investment ROI from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Neuphoria Therapeutics Inc   (NASDAQ: NEUP)


Neuphoria Therapeutics Inc's ROI from its fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Neuphoria Therapeutics Inc's ROI in the fourth quarter of 2026?
Neuphoria Therapeutics Inc recorded a cumulative net loss of $-13 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on investment (ROI) of -45.4%.

Within the Healthcare sector 510 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2026 from 3177 to 3979.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
IV. Quarter		 (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter		 (Jun 30 2025)
IV. Quarter
Y / Y Investment Change TTM 36.7 % 39.62 % 40.18 % 1.74 % -8.01 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 28 32 38 21 24
Return On Investment (TTM) -45.4 % -60.93 % -20.43 % -42.97 % -1.71 %
NEUP's Overall Ranking # 3979 # 3177 # 2284 # 3227 # 2389
Seq. Investment Change TTM 3.57 % 3.18 % 25.77 % 1.71 % 5.78 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -13 -17 -6 -9 0

NEUP Company Profile >> Back to NEUP Roi Comparisons >> See Annual NEUP Return On Investment



Return On Investment NEUP's Ranking
Within: No.
Industry # 221
Sector # 511
Overall # 3979

Return On Investment Statistics
High Average Low
-2.05 %
-52.93 %
-108.23 %
(Jun 30 2025)   (Sep 30 2024)



  News about Neuphoria Therapeutics Inc Return on Investment ROI

Neuphoria Therapeutics Reports Strong First Quarter 2025 Business Updates Amid Promising Stock Performance

May 20, 2025

Neuphoria Therapeutics Reports Strong First Quarter 2025 Business Updates Amid Promising Stock PerformanceBURLINGTON, Mass. May 20, 2025 – Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a forward-thinking, clinical-stage biotechnology firm specializing in innovative treatments for neuropsychiatric disorders, has released significant business updates for the first quarter of 2025. This announcement arrives at a time when the company’s stock is demonstrating resilience and growth, trading 4.1% above its 52-week average.Over the last quarter, Neuphoria has made notable strides in both research and corporate strategy, showcasing its commitment to addressing critical gaps in the treatment of neuropsychiatric conditions. The company is heavily focused on developing therapies that not only aim to alleviate symptoms but also target the root causes of these disorders, positioning itself as a leader in an increasingly competitive field.





Financial Statements
Neuphoria Therapeutics Inc's IV. Quarter Investments $ 28 Millions NEUP's Balance sheet
Neuphoria Therapeutics Inc's IV. Quarter Income $ -5 Millions Quarterly NEUP's Income Statement
NEUP's Income by Division See NEUP's Income by Division


NEUP Annual Return On Investment (Jun 30 2026)
2026		 (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022
Total Investments in Millions 28 26 19 28 44
Y / Y Investment Growth 8.84 % 34.19 % -31.05 % -36.5 % -
Net Income in Millions -13 0 -15 -21 -16
Y / Y Net Income Growth - - - - -
Annual Return On Investment -48.12 % -1.44 % -80.95 % -77.03 % -36.12 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NEUP's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NEUP's Competitors
Subscribers only: Roi for Neuphoria Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for NEUP's Customers

Other Ratios
NEUP's Roa NEUP's Inventory Turnover Ratio NEUP's Growth Rates NEUP's Dividend Statistics
NEUP's Profitability Ratios NEUP's Asset Turnover Ratio NEUP's Dividend Growth
NEUP's Roe NEUP's Valuation Ratios NEUP's Financial Strength Ratios NEUP's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-19T15:06:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.